First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

NCT06625515 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by sponsor based on the adverse event profile.

Conditions

Advanced Solid Tumors
Breast Cancer Recurrent
Colorectal Cancer Metastatic
Colon Cancer
Rectal Adenocarcinoma
Endometrial Cancer

Interventions

DRUG: ATX-559

Sponsor

Accent Therapeutics